Deep-Priming™ Technology Platform

Our Deep-Priming platform is based on more than 10 years of research and development focused on very potent immunomodulatory drugs—cytokines, antibodies, and small molecules—that have the ability to activate and protect T cells from the “hostile” tumor microenvironment. Normally, administering these immuno-modulatory drugs systemically to a patient can cause lethal toxicity due to activation of immune cells throughout the body. Deep-Primed immune cell therapeutics are designed to preferentially activate the immune response locally in the tumor microenvironment, which is achieved by anchoring the immunomodulatory drugs to the surface of the T cells.

We call these T cells with anchored drugs “Deep-Primed™” immune cell therapeutics, which we engineer to either:

  • act on the carrier cell itself (this is known as an autocrine signaling loop), so that the drug is released at the cell surface and binds to the cell’s own receptors; or
  • deliver a drug that activates other immune cells in the microenvironment (this is known as a paracrine signaling loop) to boost the immune response by recruiting other immune cells for a durable, long-lasting anti-tumor efficacy.

Torque Deep-Primed™ Immune Cell Therapeutics

Deep-Priming involves two key steps:

  1. Polymerize the immunomodulatory drugs to form high-density doses of Deep-Priming cytokine, connected with a reversible cross-linker
  2. Attach the Deep-Priming cytokine to the carrier T cell, anchoring it to proteins on the T cell surface.

We design the anchor and cross-linkers to respond to the biology of the cell when it finds the tumor, to ensure local release in the tumor microenvironment. In this way, Deep Priming supercharges the T cell to attack the tumor by releasing the drug in the tumor microenvironment.

Deep-Primed T cells retain all the natural functions of natural T cells, including:

  • trafficking to tissues
  • recognizing tumors
  • destroying tumor cells
Deep-Primed T Cells on the move:
This video shows Deep-Primed T cells migrating through a collagen matrix in cell culture. The blue flashlights visible on the tail of each cell are clustered immunomodulatory drugs carried by the T cell surface receptors. The biotherapeutic components have been moved to the rear of the cell, because that’s where the T cell carries those receptors.
A Deep-Primed T cell recognizes and infiltrates its target:
When the Deep-Primed T cell encounters a tumor cell (green), the Deep-Priming cytokine on its cell surface (blue) starts moving into the interface. The blue speckles show the early stages of the T cell moving the cluster of cytokines into the interface with the tumor cell, where the drug cross-linkers can dissolve and release the drug in a controlled and measured process.
Back to Top